Recent Advances in Glioma Cancer Treatment: Conventional and Epigenetic Realms

Overview

Journal Vaccines (Basel)

Date 2022 Sep 23

PMID 36146527

Authors

Mohsen Karami Fath

Kimiya Babakhaniyan

Mehran Anjomrooz

Mohammadrasoul Jalalifar

Seyed Danial Alizadeh

Zeinab Pourghasem

Parisa Abbasi Oshagh

Ali Azargoonjahromi

Faezeh Almasi

Hafza Zahira Manzoor

Bahman Khalesi

Navid Pourzardosht

Saeed Khalili

Zahra Payandeh

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is the most typical and aggressive form of primary brain tumor in adults, with a poor prognosis. Successful glioma treatment is hampered by ineffective medication distribution across the blood-brain barrier (BBB) and the emergence of drug resistance. Although a few FDA-approved multimodal treatments are available for glioblastoma, most patients still have poor prognoses. Targeting epigenetic variables, immunotherapy, gene therapy, and different vaccine- and peptide-based treatments are some innovative approaches to improve anti-glioma treatment efficacy. Following the identification of lymphatics in the central nervous system, immunotherapy offers a potential method with the potency to permeate the blood-brain barrier. This review will discuss the rationale, tactics, benefits, and drawbacks of current glioma therapy options in clinical and preclinical investigations.

Citing Articles

The Small Molecules of Plant Origin with Anti-Glioma Activity.

Liu X, Su Y, Yang Y, Li R, Zhang Z Int J Mol Sci. 2025; 26(5).

PMID: 40076568 PMC: 11900624. DOI: 10.3390/ijms26051942.

Mucins as Precision Biomarkers in Glioma: Emerging Evidence for Their Potential in Biospecimen Analysis and Outcome Prediction.

Erickson A, Jackson L, Camphausen K, Krauze A Biomedicines. 2025; 12(12.

PMID: 39767713 PMC: 11673638. DOI: 10.3390/biomedicines12122806.

Dual roles of extracellular vesicles in acute lymphoblastic leukemia: implications for disease progression and theranostic strategies.

Lajevardi M, Ashrafpour M, Mubarak S, Rafieyan B, Kiani A, Noori E Med Oncol. 2024; 42(1):11.

PMID: 39572459 PMC: 11582151. DOI: 10.1007/s12032-024-02547-7.

Bibliometric and visualization analysis in the field of epigenetics and glioma (2009-2024).

Zeng Y, Tao G, Zeng Y, He J, Cao H, Zhang L Front Oncol. 2024; 14:1431636.

PMID: 39534093 PMC: 11555291. DOI: 10.3389/fonc.2024.1431636.

Intraoperative fluorescence redefining neurosurgical precision.

Regmi M, Li Y, Wang Y, Liu W, Dai Y, Liu S Int J Surg. 2024; 111(1):998-1013.

PMID: 38913424 PMC: 11745677. DOI: 10.1097/JS9.0000000000001847.

References

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Gabrusiewicz K, Ellert-Miklaszewska A, Lipko M, Sielska M, Frankowska M, Kaminska B . Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One. 2011; 6(8):e23902. PMC: 3162015. DOI: 10.1371/journal.pone.0023902. View

Myant K, Termanis A, Sundaram A, Boe T, Li C, Merusi C . LSH and G9a/GLP complex are required for developmentally programmed DNA methylation. Genome Res. 2010; 21(1):83-94. PMC: 3012929. DOI: 10.1101/gr.108498.110. View

Chen X, Zhang L, Zhang I, Liang J, Wang H, Ouyang M . RAGE expression in tumor-associated macrophages promotes angiogenesis in glioma. Cancer Res. 2014; 74(24):7285-7297. PMC: 4268204. DOI: 10.1158/0008-5472.CAN-14-1240. View

Zang L, Kondengaden S, Che F, Wang L, Heng X . Potential Epigenetic-Based Therapeutic Targets for Glioma. Front Mol Neurosci. 2018; 11:408. PMC: 6249994. DOI: 10.3389/fnmol.2018.00408. View

Rajaratnam V, Islam M, Yang M, Slaby R, Ramirez H, Mirza S . Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. Cancers (Basel). 2020; 12(4). PMC: 7226351. DOI: 10.3390/cancers12040937. View

Finck A, Gill S, June C . Cancer immunotherapy comes of age and looks for maturity. Nat Commun. 2020; 11(1):3325. PMC: 7335079. DOI: 10.1038/s41467-020-17140-5. View

Qiu S, Lu L, Qiao C, Wang L, Wang Z, Xiao X . Induction of tumor immunity and cytotoxic t lymphocyte responses using dendritic cells transduced by adenoviral vectors encoding HBsAg: comparison to protein immunization. J Cancer Res Clin Oncol. 2005; 131(7):429-38. DOI: 10.1007/s00432-004-0616-1. View

Garber K . China approves world's first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006; 98(5):298-300. DOI: 10.1093/jnci/djj111. View

10.

Badie B, Schartner J . Flow cytometric characterization of tumor-associated macrophages in experimental gliomas. Neurosurgery. 2000; 46(4):957-61; discussion 961-2. DOI: 10.1097/00006123-200004000-00035. View

11.

Del Vecchio C, Calistri A, Parolin C, Mucignat-Caretta C . Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma. Cancers (Basel). 2019; 11(3). PMC: 6468594. DOI: 10.3390/cancers11030417. View

12.

Masumoto H, Hawke D, Kobayashi R, Verreault A . A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response. Nature. 2005; 436(7048):294-8. DOI: 10.1038/nature03714. View

13.

Ye X, Xu S, Xin Y, Yu S, Ping Y, Chen L . Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J Immunol. 2012; 189(1):444-53. DOI: 10.4049/jimmunol.1103248. View

14.

Kohnke T, Krupka C, Tischer J, Knosel T, Subklewe M . Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015; 8:111. PMC: 4599591. DOI: 10.1186/s13045-015-0213-6. View

15.

Boohaker R, Lee M, Vishnubhotla P, Perez J, Khaled A . The use of therapeutic peptides to target and to kill cancer cells. Curr Med Chem. 2012; 19(22):3794-804. PMC: 4537071. DOI: 10.2174/092986712801661004. View

16.

Shankar G, Kirtane A, Miller J, Mazdiyasni H, Rogner J, Tai T . Genotype-targeted local therapy of glioma. Proc Natl Acad Sci U S A. 2018; 115(36):E8388-E8394. PMC: 6130372. DOI: 10.1073/pnas.1805751115. View

17.

Gupta B, Levchenko T, Torchilin V . TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res. 2007; 16(8):351-9. DOI: 10.3727/000000006783980946. View

18.

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

19.

Chiocca E, Abbed K, Tatter S, Louis D, Hochberg F, Barker F . A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. Mol Ther. 2004; 10(5):958-66. DOI: 10.1016/j.ymthe.2004.07.021. View

20.

Vauleon E, Tony A, Hamlat A, Etcheverry A, Chiforeanu D, Menei P . Immune genes are associated with human glioblastoma pathology and patient survival. BMC Med Genomics. 2012; 5:41. PMC: 3507656. DOI: 10.1186/1755-8794-5-41. View